Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.

Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F

European journal of endocrinology1 Aug 1999Cited by 64 (Europe PMC)

PMID10427157DOI10.1530/eje.0.1410140PepBankPUB-10427157

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In girls with central precocious puberty, height SDS decreased during Decapeptyl treatment.
In plain wordsIn girls with early puberty, height scores decreased during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight SDS
Study
n = 71
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
Height SDS
1.5 SDS
before treatment
Height SDS
0.9 SDS
during treatment
Source sentences
Summary
During the entire treatment period we observed: (a) a decrease of height standard deviation scores (SDS) (from 1.5+/-1.7 to 0.9+/-1.3 SDS, P<0.01);
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715701
02HumanObservational studyEfficacy outcome
In girls with central precocious puberty, bone age progression slowed during Decapeptyl treatment.
In plain wordsIn girls with early puberty, bone maturation slowed during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBone age progression
Study
n = 71
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
DeltaBA:DeltaCA
0.2 ratio
during treatment
Source sentences
Summary
(b) a striking deceleration of bone age (BA), revealed by the subnormal DeltaBA:Deltachronological age (CA) ratio (0.2+/-0.1);
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715702
03HumanObservational studyEfficacy outcome
In girls with central precocious puberty, predicted adult height increased during Decapeptyl treatment.
In plain wordsIn girls with early puberty, predicted adult height increased during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height
Study
n = 71
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
Predicted adult height
155.6 cm
before treatment
Predicted adult height
160.7 cm
end of therapy
Source sentences
Summary
(c) an increase of predicted adult height (from 155.6+/-7.0 to 160.7+/-6.7 cm, P<0.0005).
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715703
04HumanObservational studyEfficacy outcome
In treated girls, final height after Decapeptyl interruption was lower than height predicted at treatment completion.
In plain wordsIn treated girls, final height after Decapeptyl stopped was lower than predicted at treatment completion.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFinal height after treatment interruption
Study
n = 71
Comparator
Height predicted at the end of therapy
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
Final height
158.4 cm
after treatment interruption
Source sentences
Summary
Treatment interruption was followed by an important catch-down growth, with an FH (158.4+/-5.8 cm) lower (P<0.025) than that predicted at the end of therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715704
05HumanObservational studyEfficacy outcome
Among girls treated with Decapeptyl, final height was within the population norm in 87.3%.
In plain wordsAmong girls treated with Decapeptyl, 87.3% reached final height within the population norm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height within population norm
Study
n = 71
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
Within population norm
87.3%
treated girls
Source sentences
Summary
However, FH fell within the population norm and the target range in respectively 87.3 and 90% of the patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715705
06HumanObservational studyEfficacy outcome
Among girls treated with Decapeptyl, final height was within the target range in 90%.
In plain wordsAmong girls treated with Decapeptyl, 90% reached final height within their target range.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height within target range
Study
n = 71
Outcome group
Linear growth · Endocrine and hormones
Studied dose
60 microg/kg every 28 days · intramuscular · at least 2 yearsAs given in this study (human).
Measurements
Within target range
90%
treated girls
Source sentences
Summary
However, FH fell within the population norm and the target range in respectively 87.3 and 90% of the patients.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy…
Report a problemFND-1042715706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.